+ All Categories
Home > Documents > THE NEW SIGN GUIDELINES Malcolm Metcalfe Aberdeen Royal Infirmary.

THE NEW SIGN GUIDELINES Malcolm Metcalfe Aberdeen Royal Infirmary.

Date post: 18-Dec-2015
Category:
Upload: lynn-phillips
View: 225 times
Download: 2 times
Share this document with a friend
Popular Tags:
30
THE NEW SIGN GUIDELINES Malcolm Metcalfe Aberdeen Royal Infirmary
Transcript

THE NEW SIGN GUIDELINES

Malcolm Metcalfe

Aberdeen Royal Infirmary

SIGN guidelines 6th February 2007

SIGN 93 - ACSPrinciple recommendations

• Patients with NSTEMI at medium or high risk of early recurrent cardiovascular events should undergo early coronary angiography +/- intervention.– GRACE score rather than TIMI recommended

• Patients with STEMI treated with thrombolysis should be considered for coronary angiography +/- intervention– 4 RCTs. Eg GRACIA -1, at 1 year 12% ARR, 56%RRR

combined end point.

Risk assessment using the TIMI score (JAMA 2000; 284: 835-)

GRACE scorewww.outcomes-umassmed.org/grace

The in-hospital GRACE model was based upon data from 11,389 patients with either an STEMIor a non-ST elevation ACS (1). This model was then validated based upon data from anadditional 3972 patients from GRACE and 12,142 patients from the GUSTO I Ib trial. Eightindependent risk factors were found to account foralmost 90 percent of the prognostic information:

Age

Killip class

Systolic blood pressure

Presence of ST segment deviation

Cardiac arrest during presentation

Serum creatinine concentration

Presence of elevated serum cardiac biomarkers

Heart rate

Point scores were assigned for each predictive factor and are added together to arrive at an estimate of the risk of in-hospital mortality.

Killip class

Class I - no evidence of HF

Class I I - findings consistent with mild to moderateHF (S3, lung rales less than one- half way up theposterior lung fields, or jugular venous distension)

Class I I I - overt pulmonary edema

Class IV - cardiogenic shock

Pharmacological highlights

• Clopidogrel in NSTEMI for only 3 months (saves £2M)

• All patients with established vascular disease should be on ACEI

• Patients with MI, LVD (LVEF <40%) with either heart failure or diabetes should be given eplerenone

SIGN 94 - Arrhythmias

• Defibrillation in patients with VF or pulseless VT should be administered without delay in witnessed cardiac arrests and following 2 minutes of CPR in unwitnessed cardiac arrests [B].

• Automated external defibrillators should be sited in locations which have a high probability of cardiac arrests [B].

• IV amiodarone should be considered for the management of refractory VT/VF [A]

SIGN 94 - Arrhythmias

• In AF rate control is the recommended strategy for asymptomatic patients [A]

• Ventricular rate in AF should be controlled with B blockers, rate-limiting Ca antagonists or digoxin [A].

• Ablation and pacing should be considered for patients with AF who remain severely symptomatic or who have LV dysfunction in association with poor rate

control or intolerance of rate-limiting medication [B].

SIGN 94 - Arrhythmias

• Patients 1 month after MI with symptomatic LV dysfunction (<35%) should be considered for ICD [A].

• Patients with NSVT (esp if inducible), LVEF < 25% or prolonged QRS should be offered ICD [B]

• Patients with above but also NYHA III-IV and QRS >120 should be considered for CRT-D [A]

• Patients surviving cardiac arrest in absence of ischaemia or other treatable cause should be considered for ICD [A]

SIGN 95Management of CHF

• BNP and/or ECG should be used to indicate the necessity for echocardiography in patients with suspected heart failure [A].

• A CXR is still recommended early in the diagnostic pathway to investigate other potential causes of SOB [B].

Pharmacology

• ACEIs recommended for all grades of LVSD [A]• B Blockers recommended for all stable LVSD patients

[A]• Patients intolerant of ACEI should be given ARB [A]• Patients with LVSD who are still symptomatic despite

above can be considered for an ARB as additional therapy [B]

• Digoxin should be considered as add on therapy [B]

Devices

• For patients in SR with drug refractory symptoms due to LVSD and who are in NYHA III or IV with a QRS duration >120ms - CRT should be considered [A].

• Caveats– benefit may be greatest for NYHA II-III– RBBB does not appear to benefit

Mean Follow-up 36.4 months (range 26.1 to 52.6)

CRT Deaths = 101 (24.7%) (cross-over 4.6%)

Medical Therapy Deaths = 154 (38.1%) (cross-over 23.5%)

CARE-HF Extension StudyEffect of CRT on All-Cause

Mortality

409 383 358 338 209 85404 372 331 298 178 63

CRTMedical therapy

Number at risk 96

CRT

MedicalTherapy

0 400 16000.00

0.25

0.50

0.75

1.00S

urvi

val

Time (days)800 1200

Hazard Ratio 0.60 (95% CI 0.47 to 0.77; P<0.0001)

Also 52% reduction in the rate of hospitalisation

for worsening heart failure

CARE-HF Extension StudyTime to Sudden Cardiac Death

CRT

MedicalTherapy

0 16000.00

0.25

0.50

0.75

1.00

Sur

viva

l

Time (days)400 800 1200

Medical = 54 sudden deaths (13.4%)

CRT = 32 sudden deaths (7.8%)

Absolute difference = 22 (5.6%)Mean Follow-up 36.4 months (range 26.1 to 52.6)

HR 0.54 (95% CI 0.35 to 0.84)

P=0.006

You Don't Need an ICD

to Reduce the Risk of SCD

SIGN 96 - Stable angina

• B blockers first choice [A]• Rate-limiting Ca antgonists 2nd choice [A]• All patients should receive statin and aspirin• LMS - CABG [A]• 3VD - CABG preferred [A]• Other disease either PCI or CABG [A]• B Blockers are recommended in high-risk

patients with cad undergoing non-cardiac surgery [A]

RISK FACTORS(SIGN 97 RISK ESTIMATION & PREVENTION

OF CORONARY DISEASE)

• Change in emphasis to embrace social deprivation (ASSIGN)– classical risk factors– FH if <60 years– SIMD (by postcode)

• Calculation will be via computer desktop and value expressed as continuous variable.

RISK FACTOR MANGEMENT

– age– sex– smoking status– BP– DM– waist/Hip ratio– dietary pattern– physical activity– alcohol consumption– lipid levels– psychosocial factors (“stress”)

Framingham factors underestimate risk in high risk individuals (eg social deprivation)

PREDICTED AND OBSERVED HEART DEATHS IN RENFREW PAISLEY (MIDSPAN)

0

5

10

15

20

25

1 2 3 4 5

Quintiles of Framingham risk

CV

D m

ort

alit

y % Observed

Predicted

Is it feasible, will it do any good?

• Whilst good evidence that deprivation score is proportional to risk little evidence that targeting it will gain advantage (level D evidence)

• Makes things more complex

• Expensive– statins £43M, better BP control £2.8M

Avoid bad habits...Avoid bad habits...

TREATMENT THRESHOLD

• Individuals should be considered to be at high risk if the chance of an initial major vascular event is >20% over 10 years.

What level to treat to?

Absolute Reduction in LDL-Cholesterol (mmol/l) and Absolute Reduction in Risk of

Major Cardiac Event (MCE)

4S

A TO Z

AF/Tex-CAPSASCOT

CARDS

GREACEHPS

LIPID

LIPS

LRC-CPPTMIRACL

PROVE-IT

Post-CABG

WOSCOPS

.

.

.

CARE

PROSPER

Intervention/SecondaryIntervention/Primary

Intervention/Both

Control/SecondaryControl/Primary

Control/Both

0%10

%20

%30

%M

ajor

Car

diac

Eve

nt (

%)

1 2 3 4 5LDL-Cholesterol (mmol/l) Adapted from Joint British

Societies’ Guidelines1

STATIN EXPENSE

• The more aggressive the policy the more expensive the treatment.

• Benefits unclear.• Recommendation therefore to keep to

existing standards of achieving TC <5mmol/l (LDL <3) This however is the minimum standard and for certain high risk patients a more aggressive policy may be appropriate

ASPIRIN

• Despite widespread belief of benefit still controversial.– no dispute re secondary prevention– more complex for primary prevention

• reduces MI by 30% in males, 0% in females• increases haemorrhagic CVA by 40%• increases gi bleeding by 70%• generally no overall benefit

• however when cvs risk >15% may be of net benefit.

• Consider use for high risk individuals

ACEIs for patients with vascular disease but not LV systolic dysfunction

• Good evidence for benefit in higher risk patients (level A)– PVD– CVD– Diabetes

• No evidence of significant benefit for low-risk individuals

HOPE study

And finally...


Recommended